Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

c-Myc phosphorylation by PKCζ represses prostate tumorigenesis.

Kim JY, Valencia T, Abu-Baker S, Linares J, Lee SJ, Yajima T, Chen J, Eroshkin A, Castilla EA, Brill LM, Medvedovic M, Leitges M, Moscat J, Diaz-Meco MT.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6418-23. doi: 10.1073/pnas.1221799110. Epub 2013 Apr 2.

2.

Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.

Kim J, Roh M, Abdulkadir SA.

BMC Cancer. 2010 Jun 1;10:248. doi: 10.1186/1471-2407-10-248.

3.

Ezrin mediates c-Myc actions in prostate cancer cell invasion.

Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, Pang ST, Norstedt G, Pousette A, Flores-Morales A.

Oncogene. 2010 Mar 11;29(10):1531-42. doi: 10.1038/onc.2009.442. Epub 2009 Dec 14.

PMID:
20010876
4.

Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.

Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J.

Oncogene. 2009 Sep 17;28(37):3307-19. doi: 10.1038/onc.2009.181. Epub 2009 Jul 13.

5.

GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction.

Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC.

Cancer Res. 2011 Dec 15;71(24):7694-704. doi: 10.1158/0008-5472.CAN-11-1714. Epub 2011 Oct 24.

6.

Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.

Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA.

PLoS Genet. 2009 Jul;5(7):e1000542. doi: 10.1371/journal.pgen.1000542. Epub 2009 Jul 3.

7.

ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc.

Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S.

Oncogene. 2014 Dec 4;33(49):5582-91. doi: 10.1038/onc.2013.505. Epub 2013 Dec 9.

PMID:
24317511
8.

RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.

Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC.

Cancer Discov. 2014 Mar;4(3):318-33. doi: 10.1158/2159-8290.CD-13-0346. Epub 2014 Jan 20.

9.

MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG, Dang CV, Xu M, Anele U, Koh CM, Bieberich CJ, De Marzo AM.

PLoS One. 2010 Feb 25;5(2):e9427. doi: 10.1371/journal.pone.0009427.

10.

Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.

Dixon KM, Lui GY, Kovacevic Z, Zhang D, Yao M, Chen Z, Dong Q, Assinder SJ, Richardson DR.

Br J Cancer. 2013 Feb 5;108(2):409-19. doi: 10.1038/bjc.2012.582. Epub 2013 Jan 3.

11.

Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.

Koh CM, Gurel B, Sutcliffe S, Aryee MJ, Schultz D, Iwata T, Uemura M, Zeller KI, Anele U, Zheng Q, Hicks JL, Nelson WG, Dang CV, Yegnasubramanian S, De Marzo AM.

Am J Pathol. 2011 Apr;178(4):1824-34. doi: 10.1016/j.ajpath.2010.12.040.

12.

Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis.

Berger PL, Frank SB, Schulz VV, Nollet EA, Edick MJ, Holly B, Chang TT, Hostetter G, Kim S, Miranti CK.

Cancer Res. 2014 Jun 15;74(12):3357-68. doi: 10.1158/0008-5472.CAN-13-3076. Epub 2014 Apr 24.

13.

Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway.

Tang ZP, Dong QZ, Cui QZ, Papavassiliou P, Wang ED, Wang EH.

PLoS One. 2013 Jun 12;8(6):e63676. doi: 10.1371/journal.pone.0063676. Print 2013.

14.

Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis.

Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, Doubinskaia I, van der Meer R, Hayward SW, Eischen CM, Eltoum IE, Abdulkadir SA.

J Clin Invest. 2012 May;122(5):1907-19. doi: 10.1172/JCI58540. Epub 2012 Apr 9.

15.

MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC.

Cancer Discov. 2015 Jun;5(6):636-51. doi: 10.1158/2159-8290.CD-14-1113. Epub 2015 Mar 31.

16.
17.

Irs2 inactivation suppresses tumor progression in Pten+/- mice.

Szabolcs M, Keniry M, Simpson L, Reid LJ, Koujak S, Schiff SC, Davidian G, Licata S, Gruvberger-Saal S, Murty VV, Nandula S, Efstratiadis A, Kushner JA, White MF, Parsons R.

Am J Pathol. 2009 Jan;174(1):276-86. doi: 10.2353/ajpath.2009.080086. Epub 2008 Dec 18.

18.

Protein kinase C ζ is a positive modulator of canonical Wnt signaling pathway in tumoral colon cell lines.

Luna-Ulloa LB, Hernández-Maqueda JG, Santoyo-Ramos P, Castañeda-Patlán MC, Robles-Flores M.

Carcinogenesis. 2011 Nov;32(11):1615-24. doi: 10.1093/carcin/bgr190. Epub 2011 Aug 22.

PMID:
21859831
19.

Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity.

Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R, Watt MJ, Taylor RA, Humbert P, Topisirovic I, Larsson O, Risbridger GP, Furic L.

Oncotarget. 2015 Jan 20;6(2):604-16.

20.

MYC phosphorylation at novel regulatory regions suppresses transforming activity.

Wasylishen AR, Chan-Seng-Yue M, Bros C, Dingar D, Tu WB, Kalkat M, Chan PK, Mullen PJ, Huang L, Meyer N, Raught B, Boutros PC, Penn LZ.

Cancer Res. 2013 Nov 1;73(21):6504-15. doi: 10.1158/0008-5472.CAN-12-4063. Epub 2013 Sep 12.

Supplemental Content

Support Center